Guardant Health 배당금 및 환매

배당금 기준 확인 0/6

Guardant Health 배당금을 지급한 기록이 없습니다.

주요 정보

n/a

배당 수익률

-2.4%

환매 수익률

총 주주 수익률	-2.4%
미래 배당 수익률	0%
배당금 성장	n/a
다음 배당금 지급일	n/a
전 배당일	n/a
주당 배당금	n/a
지급 비율	n/a

최근 배당금 및 환매 업데이트

업데이트 없음

Recent updates

Market Participants Recognise Guardant Health, Inc.'s (NASDAQ:GH) Revenues Pushing Shares 36% Higher

Nov 08

An Intrinsic Calculation For Guardant Health, Inc. (NASDAQ:GH) Suggests It's 44% Undervalued

Oct 25

Is There Now An Opportunity In Guardant Health, Inc. (NASDAQ:GH)?

Sep 24

Guardant Health: Top-Line Growth Undeniable, Compounding Ability Remains Unseen

Aug 21

Guardant Health, Inc.'s (NASDAQ:GH) P/S Is Still On The Mark Following 26% Share Price Bounce

Jul 31

Guardant Health, Inc. (NASDAQ:GH) Shares Could Be 49% Below Their Intrinsic Value Estimate

Jul 12

Guardant: Double-Digit Sales Projections Come At A Cost

Jun 06

Is Now The Time To Look At Buying Guardant Health, Inc. (NASDAQ:GH)?

Jun 04

Investors Appear Satisfied With Guardant Health, Inc.'s (NASDAQ:GH) Prospects As Shares Rocket 31%

May 14

Does Guardant Health (NASDAQ:GH) Have A Healthy Balance Sheet?

Mar 29

With Guardant Health, Inc. (NASDAQ:GH) It Looks Like You'll Get What You Pay For

Jan 21

결제의 안정성과 성장

배당금 데이터 가져오기

안정적인 배당: 과거에 GH 의 주당 배당금이 안정적이었는지 판단하기에는 데이터가 부족합니다.

배당금 증가: GH 의 배당금 지급이 증가했는지 판단하기에는 데이터가 부족합니다.

시장 대비 배당 수익률

Guardant Health 시장 대비 배당 수익률

GH 배당 수익률은 시장과 어떻게 비교되나요?
세그먼트	배당 수익률
회사 (GH)	n/a
시장 하위 25% (US)	1.4%
시장 상위 25% (US)	4.2%
업계 평균 (Healthcare)	1.6%
애널리스트 예측 (GH) (최대 3년)	0%

주목할만한 배당금: 회사가 최근 지급을 보고하지 않았기 때문에 하위 25%의 배당금 지급자에 대해 GH 의 배당 수익률을 평가할 수 없습니다.

고배당: 회사가 최근 지급을 보고하지 않았기 때문에 배당금 지급자의 상위 25%에 대해 GH 의 배당 수익률을 평가할 수 없습니다.

주주에 대한 수익 배당금

수익 보장: 배당금 지급이 수익으로 충당되는지 확인하기 위해 GH 의 지급 비율을 계산하기에는 데이터가 부족합니다.

주주에 대한 현금 배당금

현금 흐름 범위: GH 에서 지급을 보고하지 않았기 때문에 배당 지속 가능성을 계산할 수 없습니다.

Guardant Health 배당금 및 환매

배당금 기준 확인 0/6

주요 정보

최근 배당금 및 환매 업데이트

Recent updates

Market Participants Recognise Guardant Health, Inc.'s (NASDAQ:GH) Revenues Pushing Shares 36% Higher

Third quarter 2024 earnings: Revenues exceed analysts expectations while EPS lags behind

Guardant Health, Inc. Revises Revenue Guidance for the Year 2024

An Intrinsic Calculation For Guardant Health, Inc. (NASDAQ:GH) Suggests It's 44% Undervalued

Guardant Health, Inc. Appoints Roberto Mignone. as Class I Director

Guardant Health, Inc. to Report Q3, 2024 Results on Nov 06, 2024

Is There Now An Opportunity In Guardant Health, Inc. (NASDAQ:GH)?

Guardant Health, Inc. has filed a Follow-on Equity Offering in the amount of $400 million.

Guardant Health: Top-Line Growth Undeniable, Compounding Ability Remains Unseen

Price target increased by 7.0% to US$41.85

Second quarter 2024 earnings: Revenues exceed analysts expectations while EPS lags behind

Guardant Health, Inc. Raises Earnings Guidance for the Full Year of 2024

Guardant Health, Inc.'s FDA-Appoints Shield™? Blood Test Now Commercially Available in U.S. as a Primary Screening Option for Colorectal Cancer

High number of new directors

Guardant Health, Inc.'s (NASDAQ:GH) P/S Is Still On The Mark Following 26% Share Price Bounce

Guardant Health, Inc. to Report Q2, 2024 Results on Aug 07, 2024

Guardant Health, Inc. Introduces Major Smart Liquid Biopsy Upgrade to Market-Leading Guardant360® Test, Further Extending Its Best-In-Class Performance

Guardant Health, Inc. Announces the Appointment of Dr. Manuel Hidalgo Medina to Board of Directors

Guardant Health, Inc. (NASDAQ:GH) Shares Could Be 49% Below Their Intrinsic Value Estimate

Guardant: Double-Digit Sales Projections Come At A Cost

Guardant Health Introduces New Guardant360 Tissuenext Test with Nearly 500 Biomarkers to Identify More Treatment Options for Patients with Advanced Cancer

Is Now The Time To Look At Buying Guardant Health, Inc. (NASDAQ:GH)?

Guardant Health, Inc. Announces FDA Advisory Committee Panel Strongly Recommends Approval of Shield™ Blood Test for Colorectal Cancer Screening as a Primary Non-Invasive Screening Option

Investors Appear Satisfied With Guardant Health, Inc.'s (NASDAQ:GH) Prospects As Shares Rocket 31%

Guardant Health, Inc. Raises Financial Guidance for the Full Year of 2024

First quarter 2024 earnings: Revenues exceed analysts expectations while EPS lags behind

Guardant Health, Inc., Annual General Meeting, Jun 12, 2024

Guardant Health, Inc. to Report Q1, 2024 Results on May 09, 2024

Guardant Health to Present Data Highlighting Application of Epigenomics to Advance Precision Oncology at 2024 AACR Annual Meeting

Does Guardant Health (NASDAQ:GH) Have A Healthy Balance Sheet?

Guardant Health, Inc. Announces Results from the ECLIPSE Study Showing the Effectiveness of Its Shield Blood Test for Detecting Colorectal Cancer

Price target decreased by 7.1% to US$42.94

Full year 2023 earnings: EPS misses analyst expectations

Guardant Health, Inc. Provides Earnings Guidance for the Year 2024

Guardant Health, Inc. to Report Q4, 2023 Results on Feb 22, 2024

With Guardant Health, Inc. (NASDAQ:GH) It Looks Like You'll Get What You Pay For

Guardant Health, Inc. Announces Executive Changes

Guardant Health, Inc. Announces Tentative Date of FDA Advisory Panel Review of Shield(TM) Blood Test

Does Guardant Health (NASDAQ:GH) Have A Healthy Balance Sheet?

Guardant Health, Inc. to Appeal Federal District Court Verdict

Third quarter 2023 earnings: EPS and revenues exceed analyst expectations

Guardant Health, Inc. Provides Revenue Guidance for Full Year 2023

Guardant Health, Inc. Announces Initial Results from the PEGASUS Trial

Guardant Health, Inc. to Report Q3, 2023 Results on Nov 06, 2023

Is There Now An Opportunity In Guardant Health, Inc. (NASDAQ:GH)?

Now 20% undervalued after recent price drop

Guardant Health, Inc. Receives Coverage for Guardant Reveal from Geisinger Health Plan

Guardant Health, Inc. Receives Regulatory Approval in Japan for Guardant360®? CDx as Companion Diagnostic to ENHERTU®? for Treatment of Non-Small Cell Lung Cancer Patients with HER2 Mutations

A Look At The Fair Value Of Guardant Health, Inc. (NASDAQ:GH)

Is Guardant Health (NASDAQ:GH) A Risky Investment?

Consensus estimates of losses per share improve by 14%

Second quarter 2023 earnings: EPS and revenues exceed analyst expectations

Guardant Health, Inc. Revises Revenue Guidance for the Full Year 2023

Guardant Resolves Pending Litigation with Illumina and Enters into New Agreement to Advance Long-Term Commercial Partnership and Cancer Research

Guardant Health, Inc. to Report Q2, 2023 Results on Aug 03, 2023

Guardant Health, Inc. Announces Reimbursement Approval of Guardant360 CDx Liquid Biopsy Test in Japan

Guardant Health, Inc.(NasdaqGS:GH) dropped from Russell 1000 Dynamic Index

A Look At The Intrinsic Value Of Guardant Health, Inc. (NASDAQ:GH)

Guardant Health, Inc. has completed a Follow-on Equity Offering in the amount of $350 million.

Guardant Health, Inc. Revises Revenue Guidance for the Full Year 2023

Price target decreased by 7.1% to US$52.82

Guardant Health, Inc. Announces Management Changes

Chief Legal Officer exercised options and sold US$90k worth of stock

Does Guardant Health (NASDAQ:GH) Have A Healthy Balance Sheet?

High number of new directors

Co-CEO & Director recently bought US$2.5m worth of stock

Chief Information Officer recently sold US$193k worth of stock

Consensus EPS estimates upgraded to US$4.60 loss, revenue downgraded

Full year 2022 earnings: EPS misses analyst expectations

Guardant Health, Inc. Initiates New Study to Examine the Impact of Shield Blood Test to Increase Screening Compliance for Colorectal Cancer

Guardant Health, Inc. Receives Coverage from UnitedHealthcare for Guardant360® CDx Blood Test as Companion Diagnostic in Advanced Lung and Breast Cancer

Price target decreased by 8.4% to US$63.56

Guardant Health, Inc. to Report Q4, 2022 Results on Feb 23, 2023

Guardant Health Introduces Guardant Galaxytm Suite of Advanced Ai Analytics to Enhance Its Portfolio of Cancer Tests and Accelerate Biomarker Discovery

Guardant Health, Inc. Receives FDA Approval for Guardant360® CDx as Companion Diagnostic for Menarini Group’S ORSERDU for Treatment of Patients with ESR1 Mutations in ER+, HER2- Advanced or Metastatic Breast Cancer